The Hepatitis C Treatment Market is anticipated to reach a value of US$ 23.9 billion by the end of 2015 and US$ 71.13 billion by the end of 2024, registering a CAGR of 13.1% over the forecast period of 2016–2024.
In comparison to other developed nations, developing nations like Brazil, China, and India have a big patient pool. This raises the need for medications used to treat hepatitis C. Few nations and state governments have taken steps to reduce the spread of hepatitis C by providing specific funding for programmes that treat the disease or by subsidising certain medications. Several private NGOs raise public awareness of the hepatitis C infection and educate the populace about it. These may also be considered as drivers for the Hepatitis C treatment market.
Request for Free Sample Copy@ https://www.persistencemarketresearch.com/samples/3602
Fever, dark urine, abdominal pain, and the appearance of yellowed skin can all be signs of an infection in its critical stage. HIV infection and alcoholism are risk factors for people of all ages. Drugs used to treat the condition make up the hepatitis C treatment market.
Portion Analysis
In 2015, the combination therapy market segment accounted for around 66.2% of the total market value by medication class. Hospital pharmacies are predicted to hold the largest market share by distribution channel, accounting for 42.8% of the Hepatitis C treatment market globally by the end of 2016, while retail pharmacies are predicted to hold a 34.2% market share in 2016.
Regional analysis
The global hepatitis C treatment market was valued at US$ 23.9 Bn in 2015. North America was the largest market for hepatitis C treatment, accounting for over 45.6% revenue share of the overall market in 2015, followed by Europe with around 19.4% share. The Asia Pacific market is expected to exhibit the highest CAGR of 14.8% during the forecast period (2016–2024), followed by Latin America.
Get up to 20% discount on Full Report Purchase @ https://www.persistencemarketresearch.com/checkout/3602
Companies:
-
- AbbVie Inc.,
- Bristol-Myers Squibb Company,
- F Hoffmann-La Roche Ltd,
- Gilead Sciences, Inc.,
- Johnson & Johnson,
- Kadmon Holdings, Inc.
- Merck & Co., Inc.
Request For Customization @https://www.persistencemarketresearch.com/request-customization/3602
Hepatitis C is a viral infection primarily affecting the liver with the hepatitis C virus. It often leads to cirrhosis and further cirrhosis may develop complications such as liver failure, liver cancer, or esophageal and gastric varices. Early stage of infection typically has no symptoms.
Critical stage of infection may display symptoms such as fever, dark urine, abdominal pain, and yellow tinged skin occurrence. People with alcoholism and HIV infection of any age group are at increased risk. Hepatitis C treatment market consists of drugs used for treatment of the disease.
Related Reports:
About Us:
About Us: Persistence Market Research’s Expertise in Life Sciences and Transformational Health, Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic recommendations. Click here to learn more about how we zero in on the critical aspects of this industry.
Contact Us:
Persistence market research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com